🇺🇸 FDA
Patent

US 11707472

Compositions for the treatment of fibrosis

granted A61KA61K31/19A61K31/662

Quick answer

US patent 11707472 (Compositions for the treatment of fibrosis) held by Viking Therapeutics, Inc. expires Mon Jul 20 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Viking Therapeutics, Inc.
Grant date
Tue Jul 25 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 20 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
21
CPC classes
A61K, A61K31/19, A61K31/662, A61K31/663, A61K31/664